Rocío Díaz-Acedo

6PUBLICATIONS
6CO-AUTHORS
Molecular targetsLiquid biopsiesAutoimmunityGene and molecular therapyEpidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 12, 2024
Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study.

Isabel María Carrión-Madroñal, Rocío Díaz-Acedo, Santiago José Lora-Escobar

|Dec 19, 2023
Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer.

Rocío Díaz Acedo, Mercedes Galvan Banqueri, Silvia Artacho Criado

|Mar 13, 2023
Hypogammaglobulinemia after front-line immunochemotherapy in patients with follicular lymphoma.

Rocío Díaz Acedo, Silvia Artacho Criado, Eduardo Ríos Herranz

|Feb 24, 2022
Tagraxofusp as first-line treatment for blastic plasmacytoid dendritic cell neoplasm.

Rocío Díaz Acedo, María Ángeles Domínguez Muñoz, Clara Navajas Laguna

|Sep 24, 2021
Effectiveness and safety of eribulin for human epidermal growth factor receptor 2 negative metastatic breast cancer in a real-world population.

Rocío Díaz-Acedo, Silvia Artacho Criado, Rocío Jiménez Galán

|May 10, 2020
Indirect comparison of anti-interleukin 17 targeted biological treatments for moderate-to-severe psoriasis.

Rocío Díaz Acedo, Mercedes Galvan Banqueri, Esther Márquez Saavedra

Pageof 1